KRYS

Over the past six months, Krystal Biotech reported strong financial results for fiscal Q2 2026, with earnings per share of $1.79 exceeding estimates and global net product revenue for VYJUVEK reaching $119.2 million, a 24% increase year-over-year. Ongoing advancement in its clinical pipeline, including upcoming registrational data for KB803 and KB801, has also provided investor confidence. Analyst ratings have been largely favorable, with a consensus of 'Strong Buy' and an average target price suggesting upside potential, including Goldman Sachs reinstating coverage with a 'Buy' rating and Bank of America lifting its target. Krystal Biotech presented at several healthcare conferences, providing updates on its maturing genetic medicines platform. The stock has shown significant growth, increasing by 85.16% between October 1, 2025, and September 30, 2026, trading between a 52-week high of $382.54 and a low of $179.19, peaking at $382.54 on June 30, 2026, and bottoming at $297.02 on August 3, 2026, despite recent short-term dips. Krystal Biotech was also set to join the S&P MidCap 400 in July 2026.